StemCell Institute (JP:7096)
:7096
Top Page
StemCell Institute
(7096)
Select Model
Select Model
Rating:56Neutral
Price Target:
¥867.00
▲(9.33% Upside)
Action:ReiteratedDate:11/19/25
The overall stock score is primarily influenced by strong financial performance, particularly in revenue growth and profitability. However, the negative free cash flow and bearish technical indicators significantly impact the score. The high P/E ratio further suggests overvaluation, limiting potential upside.
Positive Factors
Revenue Growth
Consistent revenue growth (7.97% YoY) indicates the company is expanding market traction and product adoption. Over a 2-6 month horizon this supports predictable top-line momentum, provides operating leverage potential, and underpins reinvestment capacity for R&D or commercialization.
Negative Factors
Negative Free Cash Flow
Negative free cash flow signals cash burn from operations or heavy capex and can erode liquidity over time. Persisting FCF deficits require external financing or expense cuts, constraining ability to fund R&D, commercial expansion, or dividends without diluting shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth (7.97% YoY) indicates the company is expanding market traction and product adoption. Over a 2-6 month horizon this supports predictable top-line momentum, provides operating leverage potential, and underpins reinvestment capacity for R&D or commercialization.
Read all positive factors
StemCell Institute (7096) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥8.40B
Dividend YieldN/A
Average Volume (3M)28.64K
Price to Earnings (P/E)33.5
Beta (1Y)0.42
Revenue Growth2.99%
EPS Growth-52.75%
CountryJP
Employees98
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)6.12
Shares Outstanding10,246,600
10 Day Avg. Volume23,150
30 Day Avg. Volume28,640
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)5.29
Price to Sales (P/S)5.19
P/FCF Ratio-1.37K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)14.9
Revenue Forecast (FY)¥2.88B
StemCell Institute Business Overview & Revenue Model
Company Description
StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell I...
How the Company Makes Money
null...
StemCell Institute Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.70B | 2.68B | 2.48B | 2.09B | 1.78B | 1.41B |
| Gross Profit | 1.68B | 1.69B | 1.58B | 1.34B | 1.11B | 924.21M |
| EBITDA | 502.73M | 695.19M | 534.00M | 402.49M | 309.47M | 119.66M |
| Net Income | 249.97M | 385.80M | 310.98M | 198.03M | 133.73M | 62.37M |
Balance Sheet | ||||||
| Total Assets | 7.38B | 7.52B | 6.59B | 5.83B | 5.23B | 3.96B |
| Cash, Cash Equivalents and Short-Term Investments | 2.71B | 3.20B | 2.85B | 3.32B | 3.51B | 2.74B |
| Total Debt | 497.26M | 518.96M | 10.78M | 5.89M | 0.00 | 0.00 |
| Total Liabilities | 4.72B | 4.89B | 3.90B | 3.53B | 3.13B | 2.64B |
| Stockholders Equity | 2.66B | 2.63B | 2.69B | 2.30B | 2.10B | 1.32B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -10.11M | 132.97M | 39.77M | 264.81M | -164.34M |
| Operating Cash Flow | 0.00 | 467.69M | 334.63M | 99.67M | 469.29M | 239.00M |
| Investing Cash Flow | 0.00 | -259.08M | -811.77M | -285.10M | 404.17M | -520.26M |
| Financing Cash Flow | 0.00 | 146.70M | -1.33M | -869.00K | 644.37M | 0.00 |
StemCell Institute Technical Analysis
Positive
793.00
Price Trends
848.28
Negative
817.89
Positive
892.11
Negative
Market Momentum
-6.72
Positive
49.99
Neutral
49.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Positive. The current price of 793 is below the 20-day moving average (MA) of 845.30, below the 50-day MA of 848.28, and below the 200-day MA of 892.11, indicating a bearish trend. The MACD of -6.72 indicates Positive momentum. The RSI at 49.99 is Neutral, neither overbought nor oversold. The STOCH value of 49.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7096.
StemCell Institute Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ¥28.14B | -34.16 | ― | ― | -5.65% | -469.19% | |
56 Neutral | ¥8.40B | 33.49 | ― | ― | 2.99% | -52.75% | |
56 Neutral | ¥17.41B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥51.03B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.77B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥18.99B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:7096
StemCell Institute
820.00
-565.00
-40.79%
JP:4593
Healios KK
378.00
105.00
38.46%
JP:4599
StemRIM Inc.
303.00
-32.00
-9.55%
JP:4978
ReproCELL Inc.
183.00
31.00
20.39%
JP:7774
Japan Tissue Engineering Co., Ltd.
693.00
224.00
47.76%
JP:7776
CellSeed Inc.
306.00
-281.00
-47.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.